Toremifene

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


220pxpx }}
Toremifene
Systematic (IUPAC) name
2-[4-(4-chloro-1, 2-diphenyl-but-1-enyl)phenoxy]- N,N-dimethyl-ethanamine
Identifiers
CAS number 89778-26-7
ATC code L02BA02
PubChem 3005573
DrugBank APRD00391
Chemical data
Formula C26H28ClNO 
Mol. mass 405.959 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding more than 99.5%
Metabolism  ?
Half life 5 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for

Toremifene

Articles

Most recent articles on Toremifene

Most cited articles on Toremifene

Review articles on Toremifene

Articles on Toremifene in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Toremifene

Images of Toremifene

Photos of Toremifene

Podcasts & MP3s on Toremifene

Videos on Toremifene

Evidence Based Medicine

Cochrane Collaboration on Toremifene

Bandolier on Toremifene

TRIP on Toremifene

Clinical Trials

Ongoing Trials on Toremifene at Clinical Trials.gov

Trial results on Toremifene

Clinical Trials on Toremifene at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Toremifene

NICE Guidance on Toremifene

NHS PRODIGY Guidance

FDA on Toremifene

CDC on Toremifene

Books

Books on Toremifene

News

Toremifene in the news

Be alerted to news on Toremifene

News trends on Toremifene

Commentary

Blogs on Toremifene

Definitions

Definitions of Toremifene

Patient Resources / Community

Patient resources on Toremifene

Discussion groups on Toremifene

Patient Handouts on Toremifene

Directions to Hospitals Treating Toremifene

Risk calculators and risk factors for Toremifene

Healthcare Provider Resources

Symptoms of Toremifene

Causes & Risk Factors for Toremifene

Diagnostic studies for Toremifene

Treatment of Toremifene

Continuing Medical Education (CME)

CME Programs on Toremifene

International

Toremifene en Espanol

Toremifene en Francais

Businness

Toremifene in the Marketplace

Patents on Toremifene

Experimental / Informatics

List of terms related to Toremifene

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.[1]

GTx Inc. is currently conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[1]

References


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools